WFNN recommends Trestle Holdings by showing bright Future By Developing new digital imaging products.
Seattle, WA (PRWEB) January 31, 2005 -- WFNN's consistently outperforms established industry benchmark indicators. Based on in-depth research and analysis, their analysts recommend securities worldwide showing the highest probability for stock price appreciation. With constant vigil, WFNN looks for economic opportunities in the private and public company sectors.
Dr. Joseph de Beauchamp, WFNN's Chief Independent Analyst, said, Overall product sales increased 32% over the prior year while software support revenue declined 57%. Gross profit for the third quarter was $437,000 compared to gross profit of $518,000 for the comparable quarter of 2003. This sector appears to show large promise. With growth in this industry, we find this company ready to move sharply forward. We the latest funding and increases in revenue, WFNN sees the stock moving to $10 per share and reducing the minus earnings to fifty cents per share."
For brief information of this new, dynamic company, examine: http://wfnn.info displaying in the search engine section.
About WFNN: World Financial News Network provides a unique blend of data, timely information and today's technologies to assist with up-to-the-minute investment and economic values on markets and investments around the world.
About Trestle
Trestle Holdings, Inc. develops and sells digital imaging and telemedicine applications linking dispersed users and data primarily in the healthcare and pharmaceutical markets. Trestle's digital imaging products - MedMicro and ePathNet - provide a digital platform to share, store, and analyze tissue images. Trestle's legacy MedReach product provides healthcare organizations with a cost effective platform for remote examination, diagnosis, and treatment of patients. The Company's digital imaging products under development include: 1) enhancements to its ePathNet service platform for the delivery of sophisticated data mining capabilities in support of quantitative histopathology, facilitating drug development and drug safety studies 3) tools to enable workflow management, association and referencing of digital slides; and 4) image analysis tools to facilitate diagnostic screening.
Investor Relations Contact:
Michael Doherty, Chairman
Trestle Holdings, Inc. (OTC: TLHO)
199 Technology, Ste. 105
Irvine, CA 92618 (Map)
Phone: 949-673-1907
Fax: 949-673-1058
http://www.trestlecorp.com/
info@trestlecorp.com
# # #
|
